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Background: In Denmark, 23% of the adult population have allergic rhinitis. We have previously
demonstrated that a majority of hay fever patients are treated with depot-steroid injections in
violation of the guidelines. It has been hypothesised that 1e2 annual depot-steroid injections
are not harmful to the patient.
Objectives: Investigate if the depot-steroid treatment of allergic rhinitis instead of immuno-
therapy increases risk of steroid-related diseases.
Methods: A retrospective study based on Danish National Registries 1995e2011 covering diag-
noses, medications, as well as clinical outcomes. The main analysis was time dependent pois-
son regression models with results presented as rate ratios (RR), and incidence per 1000
patient years.
Steroid use was defined as minimum one injection during AprileJuly for at least three
consecutive years. Treatment with specific immunotherapy against grass, birch or both was
used as non-steroid control group. Relative risk of adverse outcomes such as osteoporosis, in-
fections, diabetes and/or tendon rupture was investigated.
Results: We identified 47,382 individuals with rhinitis; 55.8% treated with steroids, 37.6% with
immunotherapy, and 6.7% with both. No significant differences in infections or tendon rupture
were observed. For steroid treatment RR of diabetes was 1.5 (95% CI: 1.3e1.8; P < 0.001),CIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; AIT, allergen immunotherapy
ARIA, allergic rhinitis and its impact on asthma; ATC, Anatomical Therapeutic Chemical Classification;
ation of Diseases and Related Health Problems ICD; RR, rate ratios; COPD, chronic obstructive pul-
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Steroids used to treat allergic rhinitis increase risk of osteoporosis and diabetes 1853incidence 3.9 (95% CI: 3.5e4.3), and RR of osteoporosis was 1.2 (95% CI: 1.0e1.5; P Z 0.023),
incidence 2.8 (95% CI: 2.5e3.1). Risk of diabetes culminated within the first two years of treat-
ment start.
Conclusions: Compared to immunotherapy regular use of depot-steroid injections to treat
allergic rhinitis is associated with increased risk of being diagnosed with diabetes and osteopo-
rosis.
Clinical implications: Treating seasonal allergic rhinitis with depot-steroid injections should be
abandoned and replaced with immunotherapy, as annual depot-steroid treatment is associated
with increased risk of diabetes and osteoporosis.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Allergic respiratory diseases have increased over the past
decades, and currently 500 million people worldwide suffer
from allergic rhinitis (here termed rhinitis) [1], and 23% of
the adult population in Denmark have allergic rhinitis [2].
One of the most comprehensive classification and treat-
ment recommendations for rhinitis is described in The
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines.
ARIA recommends initial treatment with over-the-counter
drugs like oral or intranasal antihistamines, followed by
intranasal corticosteroids, and in the case of moderate-
severe rhinitis specific immunotherapy (SIT) [3]. The effi-
cacy and safety of SIT is well documented, both for sub-
cutaneous treatment [4] and for the new sublingual
tablet alternative [5]. Systemic corticosteroids are only
recommended in the most severe cases of rhinitis and solely
on a short-term oral treatment. However, we have previ-
ously shown that depot-injections of corticosteroids are
regularly used to treat rhinitis caused by birch (Betula
Verrucosa) and grass (Phleum pratense) pollen in Denmark,
with an immunotherapy to steroid ratio of 1:14 respectively
[6]. Severe adverse events like necrosis and hypocorticism,
due to depot-steroid injections, have been reported pre-
viously [7e11]. However, firm knowledge of the risk of
developing tendon ruptures, infections and common endo-
crine diseases including diabetes and osteoporosis are ur-
gently needed [12,13].
The present nationwide study aimed to investigate if
compared to immunotherapy the use of depot-steroid in-
jections increased the relative risk of developing common
steroid-related diseases [13].Methods
Design
The study was designed as a registry-based, retrospective
study using different Danish National Registry databases. All
residents in Denmark are assigned a permanent, personal
and unique civil registration number, which enables indi-
vidual linkage of all nationwide registers. The main registry
used for this study was the Danish Register of Medicinal
Product Statistics (hereafter termed the prescription regis-
ter), which contains all information on dispensed pre-
scriptions from Danish pharmacies since 1995, where drugs
are classified according to the Anatomical TherapeuticChemical Classification (ATC) system. Because the state-
financed healthcare system partially reimburses drug ex-
penses, all Danish pharmacies are obliged to register all
dispensed drug prescriptions, ensuring a valid and accurate
register [14]. The prescription register was combined with
the Central Person Registry to ascertain fatalities during the
study period. This civil registration number is connected to
The Danish National Patient Registry, which contains infor-
mation on hospital admissions with diagnoses coded ac-
cording to the International Statistical Classification of
Diseases and Related Health Problems (ICD) [15].
Study population
The data used in this study originated from registries based
on data collected 1995e2011.
Inclusion criteria were: 1) Subcutaneous or sublingual-
tablet immunotherapy against grass (Phleum pratense),
subcutaneous immunotherapy against birch (Betula verru-
cosa) (no sublingual tablet currently available in Denmark
against birch pollen), or both; and 2) at least one steroid
injection during AprileJuly for three consecutive years
1995e2011.
Exclusion criteria were: a) Immunotherapy against any
allergen other than grass or birch, b) diagnosis of chronic
obstructive pulmonary disease, c) diagnosis of rheumatic
disease, d) less than two of the following treatments: oral
or intranasal antihistamines, or intranasal corticosteroids,
and e) diagnosis of malignant disease.
A subgroup was defined as individuals who were 18e45
years old at the time of treatment start.
Definition of diagnosis based on registry data
The ICD and ATC codes used in this study to identify groups
are shown in Table 1. ICD codes used to establish diagnosis
was used as is. Drug prescriptions by ATC codes were used
by identifying prescription patterns as described in the
following.
Rhinitis treatment with depot-steroid injections was
defined as individuals receiving at least one depot-steroid-
injection in AprileJuly for three consecutive years [6].
Rhinitis treatment with immunotherapy, symptomatic
rhinitis treatment drug class, and diabetes diagnosis were
all included based on first prescription. Diabetes follow-up
was based on last occurrence of prescriptions 1995e2011.
Asthma diagnoses were established as three consecutive
years with prescriptions.
Table 1 Overview of International Statistical Classification of Diseases and Related Health Problems (ICD) and Anatomical
Therapeutic Chemical Classification (ATC) of drugs used to identify diseases.
Group definition Diagnosis Drugs
Codes beginning with ATC Description
ICD-9 ICD-10
Asthma 493 J45 R03A, R03B Inhalant steroids, beta-2-agonists and/or
muscarinic-antagonists
Cancer 140e209 C e e
Chronic Obstructive
Pulmonary Disease (COPD)
492,494,496 J44 e e
Diabetes 24900,
24908e25000
D10, E11 A10A, A10B Human insulin (commonly used to treat
Type I diabetes) or oral anti-diabetic drugs
(commonly used to treat Type II diabetes)
Osteoporosis 72309 M81e83 e e
Respiratory tract infection 46602e48499 J01e18 e e
Rheumatic disease 725e729 M35 e e
Rhinitis Symptomatic treatment e e R01AD, R06AE,
R06AX, R01AC
Intranasal corticosteroids, Subscription
antihistamines (over-the-counter drugs is
not registered in the database), Intranasal
antihistamines










e e V01AA05 Subcutaneous immunotherapy drug
Tendon rupture 84500e84501 M66 e e
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All data were extracted and examined using the SAS Sta-
tistical Software Package version 9.2 for Windows (SAS
Institute, Cary, NC, USA). Poisson regression models (SAS
proc genmod) were used to examine risk following therapy
with either steroid or immunotherapy in a time dependent
manner. Patients entered the analyses at the time when
steroid therapy or immunotherapy was established. Time
ended with a relevant event or was censored at unrelated
death, any cancer diagnosis or on 31-Dec-2011. Time was
split in 5 year intervals by both calendar year and age.
Calendar year and age were entered into models as
continuous parameters, other variables as class variables.
The assumption of linearity of continuous variables was
tested by demonstrating no importance of further inclu-
sion of quartiles of variables. The assumption of constant
risk in intervals was tested by demonstrating nearly
identical results with split at 1 year intervals. Interactions
were tested and the only relevant interaction found was
with time after start of steroid therapy. Therefore time
after steroid therapy was subdivided in the first 2 years
and later years.Ethics
The Danish Data Protection Agency approved the present
study 2007-58-0015. Register-based retrospective studies
do not require ethical approval in Denmark.Results
Total population
In the period 1995e2011 a total of 86,368 individuals
received steroid injections AprileJuly for three consecutive
years, or immunotherapy against grass or birch. The
following were excluded: 2171 (2.5%) with a diagnosis of
chronic obstructive pulmonary disease, 2955 (3.4%) diag-
nosed with rheumatic disease, 15,747 (18.2%) who did not
have at least two classes of symptomatic drug prescriptions
(intranasal/oral antihistamines, or intranasal corticoste-
roids), and lastly 18,113 (21.0%) who received immuno-
therapy for other allergies (e.g. insect venom or house dust
mites) (Table 2). The final study population totalled 47,382
(54.9%) individuals; of these 31,135 were 18e45 years old.
The mean age was 40.5 years (95% CI: 40.4e40.7) in the
steroid group, and 30.0 years (95% CI: 29.8e30.2; Wilcoxon
P < 0.001) in the immunotherapy group. In the 18e45-year-
old group the mean age in the steroid group was 33.3 years
(95% CI: 33.1e33.4), and in the immunotherapy group it was
31.7 years (95% CI: 31.6e31.9; Wilcoxon P < 0.001). A total
of 610 individuals died, and 1784 subjects were diagnosed
with cancer.
Incidence and risk of steroid-related diseases
Risks are presented as rate ratios (RR) for individuals
treated with steroids compared to immunotherapy,
Table 2 Population overview. Steroids is defined as at least three steroid injection for three consecutive pollen seasons
(AprileJuly). “Other allergy treatment” is either oral antihistamines, intranasal antihistamines, and/or nasal corticosteroids. At
least two “Other allergy treatment”s are required. Specific immunotherapy (SIT) is for either birch, or grass (subcutaneous or
Grazax) or for both.
Reason for exclusion Steroids SIT for birch
and/or grass
Steroids and SIT
for birch and/or grass
All
(None; included in study) 26428 (55.8%) 17798 (37.6%) 3156 (6.7%) 47382 (54.9%)
Diagnosed with COPD 1492 (68.7%) 652 (30.0%) 27 (1.2%) 2171 (2.5%)
Diagnosed with rheumatic disease 1804 (61.0%) 1050 (35.5%) 101 (3.4%) 2955 (3.4%)
No other allergy treatment than
steroids and no SIT
15747 (100.0%) e e 15747 (18.2%)
Received other SIT than birch
and/or grass
e 17438 (96.3%) 675 (3.7%) 18113 (21.0%)
All 45471 (52.6%) 36938 (42.8%) 3959 (4.6%) 86368 (100.0%)
Steroids used to treat allergic rhinitis increase risk of osteoporosis and diabetes 1855incidences as number per 1000 patient years. All results
were adjusted for calendar year, age, sex and asthma.
Results are shown in Table 3. No significant increase in RR
was seen for either respiratory tract infections or tendon
rupture. In the total population, RR of diabetes for steroid
treatment was 1.5 (95% CI: 1.3e1.8; P < 0.001) with an
incidence of 3.9 (95% CI: 3.5e4.3). For osteoporosis the RR
for steroid treatment was 1.2 (95% CI: 1.0e1.4; PZ 0.023)
with an incidence rate of 2.8 (95% CI: 2.5e3.1). For 18e45-
year olds, RR for diabetes for steroid treatment was 1.4
(95% CI: 1.1e1.7; P Z 0.003), and RR for osteoporosis was
1.6 (95% CI: 1.2e2.1; P Z 0.002). In the total population
treated with depot-steroids 1015 cases of diabetes and 640
cases of osteoporosis occurred during the period
1995e2011.Time-dependency of risk in relation to treatment
Survival analyses indicated that the largest risk increase for
diabetes and osteoporosis was seen within the two years
following treatment with steroids (Figs. 1 and 2). These
results were confirmed by a risk analysis of the interaction
between steroid treatment and years (<2 years after
treatment versus >2 years after treatment). Adjusted risk
for diabetes within first two years after treatment was 1.4
(95% CI: 1.2e1.7; P Z 0.007).Table 3 Incidence and risk of steroid-associated diseases. Numb









Diabetes No 283 1.8 (1.6e2.1) 1.0 .
Yes 404 3.9 (3.5e4.3) 1.5 (1.3e1.8)* <
Osteoporosis No 202 1.3 (1.1e1.5) 1.0 .
Yes 294 2.8 (2.5e3.1) 1.2 (1.0e1.5)* 0
Respiratory
tract infection
No 253 1.6 (1.5e1.9) 1.0 .
Yes 240 2.3 (2.0e2.6) 1.2 (1.0e1.4) 0
Tendon rupture No 11 0.1 (0.0e0.1) 1.0 .
Yes 13 0.1 (0.1e0.2) 1.3 (0.6e3.0) 0Diabetes follow-up
Follow-up data for diabetes treatment showed that 92.3%
of patients in the steroid group and 93.3% of patients in the
immunotherapy group received anti-diabetic treatment
during the first year after diagnosis (PZ 0.658). At the one-
year follow-up, the percentages for patients with diag-
nosed diabetes who were still receiving anti-diabetic
treatment in the steroid and immunotherapy groups were
56.9% and 62.2%, respectively (PZ 0.180). At the two-year
follow-up the corresponding percentages were 40.1% and
51.2% respectively (P Z 0.004).
Discussion
We confirmed our previous findings that a large proportion
of individuals with allergic rhinitis are treated with depot-
injections of corticosteroids regularly throughout the pollen
season (Table 2). Furthermore, we demonstrated a 50%
increased risk of being diagnosed with diabetes (P < 0.001),
and a 20% increased risk of being diagnosed with osteopo-
rosis (P Z 0.023) among individuals treated with steroids
when compared to immunotherapy (Table 3). In a subpop-
ulation of 18e45-year-old individuals, we demonstrated a
similar risk of developing diabetes (40%; P Z 0.003),







175 1.7 (1.5e2.0) 1.0 .
0.001 191 2.4 (2.1e2.8) 1.4 (1.1e1.7)* 0.003
98 0.9 (0.8e1.1) 1.0 .
.023 106 1.3 (1.1e1.6) 1.6 (1.2e2.1)* 0.002
166 1.6 (1.4e1.9) 1.0 .
.063 139 1.8 (1.5e2.1) 1.1 (0.9e1.4) 0.382
8 0.1 (0.0e0.2) 1.0 .
.555 7 0.1 (0.0e0.2) 1.1 (0.4e3.2) 0.847
Figure 1 Time-dependent risk of diabetes when subjects
receive depot-steroid injections for rhinitis, when compared to
immunotherapy. Risks adjusted for calendar-time, sex, age,
and asthma diagnosis.
1856 K. Aasbjerg et al.among the young group was 60% increased and thus even
more pronounced (Table 3). These data suggest that of the
1015 cases with diabetes and 640 cases with osteoporosis
related to depot-steroid treatment, 451 cases of diabetes
and 213 cases of osteoporosis might have been prevented
during the years 1995 and 2011 if rhinitis was treated with
immunotherapy instead of steroids.
We believe that this study provides strong evidence for
the association between depot-steroid injections and
increased risk of the unwanted side-effects of osteoporosis
and diabetes. Although incidence rates were generally low,
the relative increments in the diabetes and osteoporosis
diagnoses were surprisingly significant and tended to in-
crease with the length of treatment (Figs. 1 and 2). With
respect to diabetes, the follow-up data showed that
immediately following a diagnosis there was no differenceFigure 2 Time-dependent risk of osteoporosis when subjects
receive depot-steroid injections for rhinitis, when compared to
immunotherapy. Risks adjusted for calendar-time, sex, age,
and asthma diagnosis.between steroid and immunotherapy treated individuals in
the use of anti-diabetic treatments. Among the cases
diagnosed with diabetes based on the prescription of
glucose lowering drugs, the numbers who remained on
glucose lowering treatment decreased in both groups dur-
ing the two years observation period, ending up at only 40%
and 51% for steroids and SIT respectively (P Z 0.004). This
difference indicates that steroid-induced diabetes to a
large extent is self-limiting and thus disappears after ste-
roid treatment is discontinued. Surprisingly, no increased
risk of respiratory-tract infections was demonstrated with
steroid treatment. One reason for this may be that the
diagnosis of infections applied in this study required hos-
pitalisation, and thus only the most severe cases with in-
fections are detected. Interestingly, no increased risk with
steroid treatment was observed for tendon rupture,
possibly because of the low number of cases (24 out of
47,382 individuals).
In our initial analysis we also investigated the risk of
neoplasms and cancer, and found increased relative risks
for both in the group receiving steroid treatment. As this
random finding surprised us, we decided to exclude in-
dividuals diagnosed with cancer to eliminate the possibility
that the cancer disease by itself would result in increased
steroid treatment. However, it cannot be ruled out that the
immunosuppressive effect of repeated steroid injections
might interfere with normal cell-lifecycles and thus
inducing cancer.
A limitation of this study is that although increasing
prevalence of osteoporosis and diabetes is observed among
rhinitis patients treated with depot-steroids, we do not
know if the cumulative effect of several steroid injections
plays a role. However, our previous findings indicate that
individuals that have become adjusted to treatment with
depot-steroids seldom change to immunotherapy at a later
stage [6].
A general potential bias of any epidemiological study
based on retrospective registry data is contamination in the
group by other diseases and/or incorrect diagnosis.
Whereas the diagnosis captured in the Danish National Pa-
tient Registry are generally reliable [15], diagnosis based on
prescription drugs can be more troublesome as there is an
assumption that drugs are used appropriately by doctors as
well as patients. However, the diagnosis of allergic rhinitis
is made only rarely in a hospital setting, and is much more
common in general practice and specialist practise outside
hospital. For this reason, unfortunately, the diagnosis of
allergic rhinitis does not appear in the Patient Registry. This
issue does not, however, appear to concern individuals
undergoing specific immunotherapy, assuming that immu-
notherapy is not used on non-allergic individuals. Conse-
quently, the accuracy of the rhinitis diagnosis may mainly
concern the steroid treated individuals. The elimination of
rheumatic as well as chronic obstructive pulmonary dis-
eases and the introduction of prescription antihistamines or
intranasal corticosteroids as a prerequisite only refine the
population, thus ensuring a correct diagnosis.
Another potential bias is the significant differences in
the mean age between steroid- and immunotherapy-
treated individuals. As expected, the mean age difference
in the total population was around ten years. Since the
prevalence of most diseases increases with age, we decided
Steroids used to treat allergic rhinitis increase risk of osteoporosis and diabetes 1857to try to minimise the bias by singling out a subgroup of
18e45-year-old individuals most likely to have atopic dis-
eases and calculating incidence and risk for steroid-related
diseases. Again we observed significant increases in both
diabetes and osteoporosis, although with fading preva-
lence. These data all together does not suggest that the
differences in age between groups may explain the exten-
sive differences in diabetes and osteoporosis.
A possible confounder in our study approach is that
doctors might initiate screening for osteoporosis and/or
diabetes following treatment with steroids compared to
immunotherapy which is not associated with the same risk
factors. Accordingly, more individuals might be diagnosed
when treated with steroids as a result of the screening. The
extent to which this may have influenced the current re-
sults is unknown, but at least for diabetes, the issue may
not be trivial due to our knowledge of the disease being
very common and asymptomatic in its earliest stages,
leaving around 50% of type 2 diabetes patients undiagnosed
in most populations.
Another limitation of the study is that diabetes patients
with mild disease not requiring glucose lowering medical
treatments were not included in the study. As discussed in
our previous publications using the definition of diabetes
based on use of glucose lowering drugs [16,17], we believe
that this definition include the majority of patients with
diabetes in Denmark, and most importantly it includes the
most severe cases. In that respect, is need to be empha-
sized that the diagnostic criteria for type 2 diabetes are
arbitrarily defined, that the criteria have changed over the
years gradually becoming more inclusive, and that the day-
to-day variation of a diagnostic oral glucose tolerance test
is around 40% meaning that some randomness exists as to
whether a person with mild glucose intolerance is being
diagnosed with diabetes or not.
In conclusion; generally the side-effects of corticoste-
roids are well documented [13,18]. Although some studies
have suggested that depot-steroid injections are a safe
alternative when treating allergic rhinitis [19], several
others, including the international GA(2)LEN corporation and
the ARIA guidelines [3,20], have disputed even the basic ef-
ficacy of steroids in treating rhinitis [21e23] compared to
other treatment alternatives. Furthermore, there are
confirmed reports of steroid-associated tissue necrosis
[7,10], skin atrophy [9], reduction of cortisol levels [24], and
suppression of the hypothalamic-pituitary-adrenal axis [11].
Conclusions
The use of depot-injection corticosteroids should be
abandoned due to serious long-term side effects and be
replaced by immunotherapy, as we have previously
demonstrated that immunotherapy reduces the need for
systemic-steroid injections [6] and the safety, and efficacy
of immunotherapy has been documented in large-scale
randomized placebo-controlled trials [4,25].
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